"Today, Maryland Oncology Hematology is the largest independent Medical Oncology and Hematology group in Maryland with 30 physicians practicing in 9 locations across central Maryland. Dedicated to providing the most advanced cancer care available anywhere in an atmosphere of caring compassion."

During the past decade, Maryland Oncology Hematology, P.A. conducted 85 clinical trials. In the 10-year time frame, 85 clinical trials started and 56 clinical trials were completed, i.e. on average, 65.9% percent of trials that started reached the finish line to date. In the past 5 years, 34 clinical trials started and 37 clinical trials were completed. i.e. 108.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Maryland Oncology Hematology, P.A." #1 sponsor was "Hoffmann-La Roche" with 14 trials, followed by "Novartis Pharmaceuticals" with 12 trials sponsored, "US Oncology Research" with 8 trials sponsored, "Bristol-Myers Squibb" with 7 trials sponsored and "Pfizer" with 7 trials sponsored. Other sponsors include 88 different institutions and companies that sponsored additional 63 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Maryland Oncology Hematology, P.A." #1 collaborator was "Genentech, Inc." with 4 trials as a collaborator, "Merck Sharp & Dohme LLC" with 3 trials as a collaborator, "Pfizer" with 3 trials as a collaborator, "Sanofi" with 3 trials as a collaborator and "ARMO BioSciences" with 2 trials as a collaborator. Other collaborators include 33 different institutions and companies that were collaborators in the rest 36 trials.

According to Clinical.Site data, the most researched conditions in "Maryland Oncology Hematology, P.A." are "Breast Cancer" (19 trials), "Metastatic Breast Cancer" (9 trials), "Ovarian Cancer" (8 trials), "Carcinoma, Non-Small-Cell Lung" (6 trials) and "Non-Small Cell Lung Cancer" (6 trials). Many other conditions were trialed in "Maryland Oncology Hematology, P.A." in a lesser frequency.

Most popular intervention types in "Maryland Oncology Hematology, P.A." are "Drug" (131 trials), "Biological" (16 trials), "Other" (5 trials), "Procedure" (2 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (15 trials), "Paclitaxel" (11 trials), "Carboplatin" (9 trials), "Docetaxel" (9 trials) and "Cyclophosphamide" (6 trials). Other intervention names were less common.

The vast majority of trials in "Maryland Oncology Hematology, P.A." are 102 trials for "All" genders, 24 trials for "Female" genders and 15 trials for "Male" genders.

Currently, there are NaN active trials in "Maryland Oncology Hematology, P.A.". undefined are not yet recruiting, 21 are recruiting, 33 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 65 completed trials in Maryland Oncology Hematology, P.A., undefined suspended trials, and 15 terminated clinical trials to date.

Out of the total trials that were conducted in Maryland Oncology Hematology, P.A., 16 "Phase 1" clinical trials were conducted, 52 "Phase 2" clinical trials and 65 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 5 trials, and there were also 1 trials that are defined as “Not Applicable".